- Yale University researchers have developed an airborne method for delivering mRNA right to your lungs
- In a study on mice, the scientists created polymer nanoparticles to encapsulate mRNA, making it inhalable
- Researchers say this “new method of delivery could ‘radically change the way people are vaccinated,’” making it easier to vaccinate people in remote areas or those who are afraid of needles
- An airborne mRNA product could be used to rapidly vaccinate the masses, without their knowledge or consent
- Academic endorsement exists for the use of compulsory, covert bioenhancements, including drugs and vaccines, on the public; the U.S. government also has a history of covert bioweapon experiments
(Mercola)—Yale University researchers have developed a new airborne method for delivering mRNA right to your lungs. The team has also used the method to vaccinate mice intranasally,1 opening the door for human testing in the near future.
While scientists are hailing the creation as an easy way to vaccinate the masses, critics wonder if the development of an airborne vaccine could be used for nefarious purposes, including covert bioenhancements,2 which have already been recommended in academic literature.3
Yale Team Develops Airborne mRNA, Delivers It to Lungs
In a study on mice, Yale scientists created polymer nanoparticles to encapsulate mRNA, making it inhalable so it can reach the lungs. Courtney Malo, editor with Science Translational Medicine, which published the study, explained:4
“The ability to efficiently deliver mRNA to the lung would have applications for vaccine development, gene therapy, and more. Here, Suberi et al. showed that such mRNA delivery can be accomplished by encapsulating mRNAs of interest within optimized poly(amine-co-ester) polyplexes [nanoparticles].
Polyplex-delivered mRNAs were efficiently translated into protein in the lungs of mice with limited evidence of toxicity. This platform was successfully applied as an intranasal SARS-CoV-2 vaccine, eliciting robust immune responses that conferred protection against subsequent viral challenge. These results highlight the potential of this delivery system for vaccine applications and beyond.”
The team, led by cellular and molecular physiologist Mark Saltzman, explained that the inhalable mRNA vaccine successfully protected against SARS-CoV-2, which “opens the door to delivering other messenger RNA (mRNA) therapeutics for gene replacement therapy and other treatments in the lungs.”5
For the study, mice received two intranasal doses of nanoparticles carrying mRNA COVID-19 vaccines, which proved to be effective in the animals. In the past, lung-targeted mRNA therapies had trouble making it into the cells necessary to express the encoded protein, known as poor transfection efficiency.6
“The Saltzman group got around this hurdle in part by using a nanoparticle made from poly(amine-co-ester) polyplexes, or PACE, a biocompatible and highly customizable polymer,” a Yale University news release explained.7 In a previous study, Saltzman had tried a “prime and spike” system to deliver COVID-19 shots, which involved injecting mRNA shots into a muscle, then spraying spike proteins into the nose.8
It turned out the injection portion may be unnecessary, and Saltzman has high hopes for the airborne delivery method, beyond vaccines:9
“In the new report, there is no intramuscular injection. We just gave two doses, a prime and a boost, intranasally, and we got a highly protective immune response. But we also showed that, generally, you can deliver different kinds of mRNA. So it’s not just good for a vaccine, but potentially also good for gene replacement therapy in diseases like cystic fibrosis and gene editing.
We used a vaccine example to show that it works, but it opens the door to doing all these other kinds of interventions.”
Air Vax Could ‘Radically Change’ How People Are Vaccinated
Saltzman says this “new method of delivery could ‘radically change the way people are vaccinated,’” making it easier to vaccinate people in remote areas or those who are afraid of needles.10 But that’s not all. An airborne vaccine makes it possible to rapidly disseminate it across a population.
JD’s manually curated links for God-fearing MAGA patriots
By releasing the vaccine in the air, there’s no need to inject each person individually — which is not only time-consuming but difficult if an individual objects to the shot. This isn’t the case with an airborne vaccine, which can be released into the air without consent or even the public’s knowledge.
A similar strategy is being used with mRNA in shrimp, which are too small and numerous to be injected individually. Instead, an oral “nanovaccine” was created to stop the spread of a virus. Shai Ufaz, chief executive officer of ViAqua, which developed the technology, stated:11
“Oral delivery is the holy grail of aquaculture health development due to both the impossibility of vaccinating individual shrimp and its ability to substantially bring down the operational costs of disease management while improving outcomes …”
While the Yale scientists are targeting an intranasal mRNA product, the outcome is the same — get as many exposed as possible with the least amount of cost and effort. According to the Yale study:12
“An inhalable platform for messenger RNA (mRNA) therapeutics would enable minimally invasive and lung-targeted delivery for a host of pulmonary diseases. Development of lung-targeted mRNA therapeutics has been limited by poor transfection efficiency and risk of vehicle-induced pathology.
Here, we report an inhalable polymer-based vehicle for delivery of therapeutic mRNAs to the lung. We optimized biodegradable poly(amine-co-ester) (PACE) polyplexes [nanoparticles] for mRNA delivery using end-group modifications and polyethylene glycol. These polyplexes achieved high transfection of mRNA throughout the lung, particularly in epithelial and antigen-presenting cells.
We applied this technology to develop a mucosal vaccine for severe acute respiratory syndrome coronavirus 2 and found that intranasal vaccination with spike protein–encoding mRNA polyplexes induced potent cellular and humoral adaptive immunity and protected susceptible mice from lethal viral challenge. Together, these results demonstrate the translational potential of PACE polyplexes for therapeutic delivery of mRNA to the lungs.”
US Government Has History of Bioweapons Release
When you put the pieces of the puzzle together, a disturbing picture emerges. As reported by The Epoch Times, we have a history of the U.S. government taking extreme measures to mandate and promote COVID-19 shots to the public. Now, researchers have developed an airborne mRNA vaccine, offering a vehicle by which to rapidly vaccinate the masses without their knowledge or consent.13
Is there proof that the government or another entity has plans to covertly release an air vax on the population? No. But there is a history of it carrying out secret bioweapon simulations on Americans. In 1950, the U.S. Navy sprayed Serratia marcescens bacteria into the air near San Francisco over a period of six days.
Dubbed “Operation Sea Spray,” the project was intended to determine how susceptible the city was to a bioweapon attack. Serratia marcescens turns whatever it touches bright red, making it easy to track. It spread throughout the city, as residents inhaled the microbes from the air. While the U.S. military initially thought Serratia marcescens wouldn’t harm humans, an outbreak occurred, with some developing urinary tract infections as a result.
At least one person died “and some have suggested that the release forever changed the area’s microbial ecology,” Smithsonian Magazine reported.14 This wasn’t an isolated incident, as the U.S. government carried out many other experiments across the U.S. over the next 20 years.15 So, while it’s disturbing to think of an air vax experiment being conducted on an unsuspecting public, it’s not unprecedented.
Bioethics Study Promotes Covert, Compulsory Bioenhancement
Adding to the story is academic endorsement of the use of compulsory, covert bioenhancements. Writing in the journal Bioethics,16 Parker Crutchfield with Western Michigan University, Homer Stryker M.D. School of Medicine, discusses moral bioenhancements, which refers to the use of biomedical means to trigger moral improvements.
Drug treatments, including vaccines, and genetic engineering are potential examples of bioenhancements.17 Further, according to Crutchfield:18
“It is necessary to morally bioenhance the population in order to prevent ultimate harm. Moral bioenhancement is the potential practice of influencing a person’s moral behavior by way of biological intervention upon their moral attitudes, motivations, or dispositions.
The technology that may permit moral bioenhancement is on the scale between nonexistent and nascent, but common examples of potential interventions include infusing water supplies with pharmaceuticals that enhance empathy or altruism or otherwise intervening on a person’s emotions or motivations, in an attempt to influence the person’s moral behavior.”
Some argue that moral bioenhancements should be compulsory for the greater good. Crutchfield believes this doesn’t go far enough. He also wants them to be covert:19
“I take this argument one step further, arguing that if moral bioenhancement ought to be compulsory, then its administration ought to be covert rather than overt. This is to say that it is morally preferable for compulsory moral bioenhancement to be administered without the recipients knowing that they are receiving the enhancement.”
He even goes so far as to suggest “a covert compulsory program promotes values such as liberty, utility, equality and autonomy better than an overt program does.”20 So here we have evidence of academic support for covertly releasing drugs and other bioenhancements onto the public. This, combined with the creation of an airborne mRNA vaccine and the government’s history of experimenting on the public, paints an unsettling picture of the future.
Problems With mRNA COVID Shots Persist
Aside from the concerns of airborne delivery, mRNA COVID-19 shots are associated with significant risks — no matter how you’re exposed. People ages 65 and older who received Pfizer’s updated (bivalent) COVID-19 booster shot may be at increased risk of stroke, according to an announcement made by the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration.21
Further, a large study from Israel22 revealed that Pfizer’s COVID-19 mRNA jab is associated with a threefold increased risk of myocarditis,23 leading to the condition at a rate of 1 to 5 events per 100,000 persons.24 Other elevated risks were also identified following the COVID jab, including lymphadenopathy (swollen lymph nodes), appendicitis and herpes zoster infection.25
At least 16,183 people also say they’ve developed tinnitus after receiving a COVID-19 shot.26 The reports were filed with the CDC’s Vaccine Adverse Event Reporting System (VAERS) database. But considering only between 1%27 and 10%28 of adverse reactions are ever reported to VAERS, the actual number is likely much higher.
It’s because of risks like these that informed consent is essential for any medical procedure, including vaccinations. The development of airborne mRNA jabs, however, makes the possibility of informed consent being taken away all the more real.
- 1, 4 Science Translational Medicine August 16, 2023, Vol 15, Issue 709
- 2, 13 The Epoch Times September 5, 2023
- 3 Bioethics. 2019 Jan;33(1):112-121. doi: 10.1111/bioe.12496. Epub 2018 Aug 29
- 5, 6, 7, 8, 9 Yale School of Engineering & Applied Science, News & Events August 16, 2023
- 10 Bitchute, Truther’s Lair September 5, 2023, 5:09
- 11 Fish Farmer September 5, 2023
- 12 Science Translational Medicine August 16, 2023, Vol 15, Issue 709, Abstract
- 14, 15 Smithsonian Magazine July 6, 2015
- 16, 18 Bioethics. 2019 Jan;33(1):112-121. doi: 10.1111/bioe.12496. Epub 2018 Aug 29., Intro
- 17 Topoi volume 38, pages 1–5 (2019)
- 19, 20 Bioethics. 2019 Jan;33(1):112-121. doi: 10.1111/bioe.12496. Epub 2018 Aug 29., Abstract
- 21 U.S. FDA January 13, 2023
- 22, 24, 25 The New England Journal of Medicine August 25, 2021
- 23 MedPage Today August 25, 2021
- 26 NBC News April 23, 2023
- 27 Harvard Pilgrim Health Care report submitted to the U.S. Department of Health and Human Services, 2011, Page 6
- 28 BMJ 2005;330:433
Bypass Big Tech Censors
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.